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(n5 15). Median HCT-CI score was 2 (range, 0-5) (n5 25). Pts
were conditioned with either 2 Gy TBI (n5 3), or Flu 90 mg/
m2 + 2 Gy TBI (n5 23). Pts were given peripheral blood stem cells
(PBSC) (n5 24) or marrow (n5 2) grafts from HLA-identical sibs
or unrelated donors matched for 10/10 (n5 15), 9/10 (n5 5), or
8/10 (n5 1) alleles. Post-grafting immunosuppression consisted of
either CSP/MMF (n5 22), tacrolimus/MMF (n5 1), or tacroli-
mus/MMF/sirolimus (n5 3). Donor CD3 chimerism was docu-
mented in 25 pts at day 28, but was not evaluated in 1 pt who died
on day 23 after achieving normal granulocyte counts. Secondary
graft rejection occurred at day 56 in 1 pt with MDS given marrow,
who subsequently achieved full donor chimerism after a secondmye-
loablative HCTwith PBSC. Of 24 evaluable pts, 20 converted to full
donor CD3 chimerism (95-100%) while 4 remained with mixed
CD3 chimerism (15-93%). Twenty pts developed acute GVHD
(grade II5 17; III5 3) at a median of 34 (range, 9-56) days after
HCT. The cumulative incidence of chronic GVHD was 51% at 2
yrs. Causes of death included disease progression/relapse (n5 13),
complications of GVHD (n5 4), or sepsis/pulmonary complications
(n5 2). The 2 year overall survival (OS), progression-free survival,
relapse, and non-relapse mortality were 49%, 28%, 58% and 14%,
respectively. On univariate analysis, pts with HCT-CI$3 had worse
OS (p5 0.008). In this small cohort, there was no survival benefit for
pts withmyeloid vs lymphoidmalignancies or disease status at HCT.
In conclusion, NM-HCT remains an important curative option for
a subset of high-risk pediatric pts who would otherwise not qualify
for high-dose therapy, with relapse being the highest contributor
to overall mortality.239
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We report the outcomes of all pediatric patients who received
high-dose chemotherapy with autologous stem cell rescue for
craniospinal (CNS) tumors at our institution. Thirty-two patients
underwent 38 autologous transplants between 2002 and 2009.
The population included 15 males and 17 females with a median
age of 66 months at diagnosis and 87 months at transplant. The
underlying diseases were medulloblastoma (56%), PNET (25%),
ATRT (13%), and pinealoblastoma (6%). Thirty-seven percent
of patients were treated for high-risk disease upfront, whereas
63% were treated for recurrent or progressive disease. The me-
dian pretransplant GFR was 119 ml/min/1.73 and 62% had hear-
ing loss. No patients had significant pre-HSCT cardiopulmonary
dysfunction. Conditioning regimens included carboplatin/thio-
tepa/etoposide (61%), carboplatin/thiotepa (21%), carboplatin/
thiotepa/VP16 (5%), thiotepa/etoposide (5%), and other (8%).
Of those that received a carboplatin-based regimen, 11% had
dose-reduction due to pre-existing organ toxicity. Median time
to engraftment was 11 days. Of the 97% of patients who survived
to discharge, the median duration of hospitalization was 20 days.
Acute complications included infection (37%), hypertension
(16%), VOD (13%), respiratory compromise (13%), renal failure
(11%), and CNS hemorrhage (8%). Four patients (11%) required
ICU care. Late complications included transverse myelitis (2 pa-
tients), varicella zoster (2 patients), and esophageal stricture (2
patients). Progressive hearing loss was reported in 9 patients.
The median duration of follow-up was 502 days. The overall sur-
vival was 72% and progression-free survival was 56%. All deaths
after discharge were due to progressive disease. Of the 12 pa-
tients who were transplanted upfront, 11 (92%) are alive without
disease progression and 1 patient died of recurrent disease (me-
dian duration of follow-up 1290 days). Of the 20 patients trans-
planted for recurrent disease, 1 died during transplant, 6 (30%)
are alive without progression, 6 (30%) are alive with progression,
and 7 (35%) are dead due to recurrent disease (median duration
of follow-up 358 days). Autologous stem cell transplant is well-tolerated with little significant toxicity in this population. Pediat-
ric patients with CNS tumors and high-risk disease who are
treated upfront appear to have better disease-free survival than
patients with recurrent disease who undergo autologous trans-
plant.240
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The Brazilian Society of Pediatric Oncology (SOBOPE) is in the
process of developing a new national protocol for the treatment of
acute lymphoblastic leukemia (ALL). Since all transplant indications
shall balance risks and benefits of each treatment modality, we would
have to know the results of hematopoietic stem cell transplants
(HSCT) performed in our country. Therefore, we analyzed the pe-
diatric data reported in a voluntary national survey of all transplants
performed for the treatment of ALL.
Methods: A questionnaire with demographic data and transplant re-
sults was sent to all Brazilian HSCT units to get data on all consec-
utive patients transplanted for ALL. The 20 years of age cut of was
chosen to allow comparison with CIBMTR data.
Results: Twenty institutions sent their data on 532 patients# 20
years. Median age was 10 years (0.5-29), 66% male. The median in-
terval from diagnosis to transplant was 2.5 years (1 mo-19 y) and me-
dian follow-up, 3 years (9 mo-14 y). Most patients were transplanted
in second remission (CR2 – 43%), followed by advanced phases
(10% CR3 and 26% in relapse) and only 19% in CR1. Matched sib-
ling donors transplant were 74% (N5 374), with a 35% 3-year over-
all survival (OS) and event free survival (EFS). HSCT results have
significantly improved over time from 27% in the early 90’s to
46% 2005-2009 (Log rank p\0.001), in a shorter follow-up. In re-
lated donor HSCT, age, conditioning therapy (+/- TBI) and graft
source did not influence survival, but EFS was 61% in CR1, 36%
in CR2 and 22% in more advanced phases (p\0.0001). Related
and unrelated donor transplants had the same results (with no adjust-
ment). Unrelated transplants were performed in 131 patients.
Age\10 years (p5 0.004), lower disease risk (p5 0.02), the use of
cord blood (p5 0.01), and TBI (p5 0.001) were associated with
a better outcome. Unrelated donor transplants had high number of
early toxic deaths and 3-yr EFS of 46% in CR1. Compared with
CIBMTR data, related donor transplants have similar results (3-yr
EFS 61% in CR1).
In conclusion, one third of our patients had HSCT for ALL in ad-
vanced stages. Results have improved in the past years for related
transplants. Disease stage was one of the most important risk factors.
After unrelated transplants, age\10 years and the use of cord blood
had better outcomes. These results will contribute to the design of
the new pediatric ALL Brazilian protocol.
